MedTrace Logo

SAD Study of APR002 Investigating the Safety/Tolerability, Pharmacokinetics/Pharmacodynamics in Healthy Subjects

NCT05268198 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2023-08-02

No results posted yet for this study

Summary

This study will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of APR002 in healthy subjects.

Conditions

Interventions

DRUG

APR002

Active Investigational Product

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • CMAX Clinical Research Pty Limited

    collaborator UNKNOWN

  • Avance Clinical Pty Ltd.

    collaborator INDUSTRY

  • Global Health Drug Discovery Institute

    lead OTHER

Principal Investigators

  • Aaron Weitzman · Global Health Drug Discovery Institute

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-20
Primary Completion
2023-06-29
Completion
2023-07-27

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05268198 on ClinicalTrials.gov